Table 1.
Cohort characteristics for participants who completed pretreatment HIV drug resistance testing and included in our primary analysis of virologic failure, divided by regimen.
| Efavirenz arm (n = 269) |
Dolutegravir arms (n = 557) |
P valuea | |
|---|---|---|---|
| Female sex (n, %) | 153 (56.9%) | 341 (61.2%) | 0.23 |
| Age (median, IQR) | 32 (27−37) | 32 (27−38) | 0.83 |
| Married or partner (n, %) | 60 (22.3%) | 108 (19.4%) | 0.34 |
| Tertiary education (n, %) | 18 (6.7%) | 51 (9.2%) | 0.22 |
| Employed (n, %) | 170 (63.7%) | 349 (63.8%) | 0.97 |
| Pretreatment CD4 count (n, %) | 0.58 | ||
| ≤200 cells/μL | 80 (29.7%) | 179 (32.1%) | |
| 201−350 cells/μL | 81 (30.1%) | 166 (29.8%) | |
| 351−500 cells/μL | 58 (21.6%) | 99 (17.8%) | |
| >500 cells/μL | 50 (18.6%) | 118 (20.3%) | |
| Pretreatment viral load (n, %) | 0.33 | ||
| <10,000 copies/mL | 89 (33.1%) | 171 (30.7%) | |
| 10,000−100,000 copies/mL | 113 (42.0%) | 264 (47.4%) | |
| >100,000 copies/mL | 67 (24.9%) | 122 (21.9%) | |
| Low self-reported adherenceb (n, %) | 113 (42.0%) | 252 (45.2%) | 0.38 |
| Pill count adherence (n, %)c | 0.45 | ||
| <90% | 12 (4.5%) | 33 (6.3%) | |
| 90−95% | 23 (8.6%) | 58 (10.5%) | |
| 95−100% | 233 (87.0%) | 463 (83.6%) | |
| Presence of any WHO-defined pretreatment drug resistance | 20 (7.4%) | 92 (16.5%) | <0.001 |
aP values represent statistical tests comparing those included and excluded from the analytic dataset, using chi-squared testing to compare categorical variables and Mann−Whitney nonparametric tests to compare median age.
bLow adherence defined as self-report of less than perfect adherence in the 4 days prior to any study visits during the observation period.
cPill count was calculated at each visit by study pharmacists, capped at 100%, then averaged across the 96-week observation period.